RadiopharmaceuticalFDA-approvedSecond-line
Radium-223
Generic name: radium-223 dichloride
How it works
Delivers radiation directly to cancer cells in the bone, killing them.
Cancer types
Prostate Cancer— All patients
Efficacy
In clinical trials, around 50% of patients achieved an objective response, with a median overall survival of approximately 14 months.
Side effects
Mild
Most people tolerate this treatment well. Side effects are generally manageable and do not require stopping treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Studying DNA Repair Pathway and Radium-223 in Prostate Cancer | Prostate Cancer | preclinical | — | Source → |
| Radium-223 Therapy for Prostate Cancer: Predictive Factors and Treatment Outcomes | Prostate Cancer | observational | — | Source → |
| Testing Radium-223 with Docetaxel in Prostate Cancer Patients | Prostate Cancer | phase-3 | — | Source → |
| Testing Olaparib with Radium-223 in Advanced Prostate Cancer | Prostate Cancer | phase-1 | — | Source → |
| Comparing Treatments for Advanced Prostate Cancer | Prostate Cancer | preclinical | — | Source → |
| Radium-223 in Biochemically Recurrent Prostate Cancer: A Phase 2 Clinical Trial | Prostate Cancer | phase-2 | — | Source → |
| Combination Therapy Shows Delayed Survival Benefit in Prostate Cancer | Prostate Cancer | phase-3 | Significant survival benefits were observed after 60 months, with RMST differences of 4.34 months (95% CI, 0.49-8.19, p = 0.03) at 60 months and 6.25 months (95% CI, 1.56-10.95, p = 0.01) at 72 months. | Source → |
| Radium-223 Treatment for Advanced Prostate Cancer | Prostate Cancer | observational | Maximum PSA and ALP declines of ≥ 30% were achieved in 16 (17.2%) and 39 (41.9%) patients, respectively. | Source → |
| Radium-223 Treatment for Prostate Cancer: Long-term Fracture Risk | Prostate Cancer | observational | The overall incidence proportion of fractures reported as adverse events was 7.76% (95% confidence interval [CI] 5.09-11.25%), with a fracture incidence rate of 5.22 patients [with fracture]/100 person-years (PY). | Source → |
| New Hope for Prostate Cancer Treatment with Radium-223 | Prostate Cancer | review | Radium-223, when administered with enzalutamide, has recently been shown to prolong radiographic progression-free survival vs. enzalutamide alone. | Source → |
| Radium-223 Treatment Linked to Longer Survival in Prostate Cancer Patients | Prostate Cancer | phase-3 | Median OS was longer in patients with than without an ALP decline (18.1 versus 14.2 months; HR 0.74; 95% CI 0.60-0.92). | Source → |
| New Biomarkers for Radium-223 Treatment in Prostate Cancer | Prostate Cancer | phase-3 | The median overall survival was 21.3 months in 22 patients. | Source → |
| Radium-223 May Help Boost Immune Response in Prostate Cancer | Prostate Cancer | animal-study | Above-median level of IL-6 at baseline was associated with a median OS of 358 versus 947 days for below levels. | Source → |
| Radium-223 Tested in Women with Advanced Breast Cancer | Breast Cancer | phase-2 | The hazard ratio for symptomatic skeletal event-free survival was 0.809 (0.610-1.072), suggesting a possible benefit. | Source → |
| Predicting Response to Radium-223 Therapy in Prostate Cancer | Prostate Cancer | phase-2 | A 48.7 SUVmax threshold identified responders with 77% sensitivity and 75% specificity. | Source → |
| Radium-223 Therapy for Metastatic Prostate Cancer: Timing and Benefits | Prostate Cancer | phase-3 | Men who received radium-223 lived longer and had less bone pain. | Source → |
| Combining Radium-223 with Hormonal Agents in Prostate Cancer | Prostate Cancer | meta-analysis | — | Source → |
| New Tool Helps Doctors Decide Who Will Benefit from Radium-223 Treatment for Advanced Prostate Cancer | Prostate Cancer | observational | The nomogram showed good discrimination, with apparent and optimism-corrected Harrell's concordance index values of 0.748 and 0.734, respectively. | Source → |
| Radium-223 Use in Prostate Cancer Patients | Prostate Cancer | observational | Despite the late cancer stage, treatment response was seen in almost half of the patients. | Source → |
| Radium-223 treatment for prostate cancer in Finland shows promise | Prostate Cancer | observational | The median overall survival was 13.8 months, and the median progression-free survival was 4.9 months. | Source → |
| Radium-223 Treatment Eases Pain in Advanced Prostate Cancer Patients | Prostate Cancer | phase-3 | Complete pain response was achieved in 31.4% of the patients, while 58% had an integrated overall clinical response. | Source → |
| Combining Treatments for Advanced Prostate Cancer | Prostate Cancer | phase-2 | Twenty-seven (90%) patients showed a reduction in alkaline phosphatase (ALP) compared with pretreatment levels. | Source → |
| Radium-223 Therapy Improves Survival in Prostate Cancer Patients | Prostate Cancer | observational | Median survival in patients who received one prior therapy was significantly improved, compared to those who received two prior therapies (448 days vs. 341 days). | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.